01.21.21 -- Using Production And Postmarket Data To Validate FMEA Assumptions
01.21.21 -- Using Production And Postmarket Data To Validate FMEA Assumptions Acepodia's Dr. Sony Hsiao, CEO, and Dr. Mark Gilbert, SVP of R&D, join Business of Biotech for a discussion on the company's approach to dramatically reducing the cost of cell therapy development, manufacturing, and administration via its oNK, CAR, and ACC candidates. Listen now and subscribe so you never miss an episode. Featured Editorial By Mark Durivage, Quality Systems Compliance LLC One common issue with regulatory agencies and certification bodies regarding failure mode a...
Source: pharmaceuticalonline.com